linjc16/ctgov huggingface dataset:
Proper Extent of Maze Intercaval Lesion

Study Overview
=================
Brief Summary
-----------------
It's hypothesized that a mean and range distance from the cavo-atrial junction to the area where there is complete loss of conductive tissue can be measured to better inform surgeons performing the Cox-Maze procedure. A patient scheduled for any cardiac surgery where visualization and mapping of cavo-atrial junction is possible could be entered into the study if they meet the inclusion/exclusion requirements.

Official Title
-----------------
Proper Extent of Maze Intercaval Lesion

Conditions
-----------------
Atrial Fibrillation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 years male or female Scheduled for any cardiac surgery where visualization and mapping of cavo-atrial junction is possible Subjects willing and able to provide written informed consent Exclusion Criteria: Subjects receiving surgery with non-sternotomy access Presence of or history of transvenous pacing leads Subjects receiving a re-do cardiac surgery Subjects with a history of pericarditis Subjects who are in atrial fibrillation or atrial flutter and cannot be converted out of it. Any medical condition or finding for which the Investigator used medical discretion to determine the subject should be excluded Subject is currently participating in another clinical trial. Subject is unable to provide written informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Distance until complete loss of conductive tissue | To measure the mean and range distance from the cavo-atrial junction to the area where there is complete loss of conductive tissue. | 6 Months |
Phase II Pilot Study of Vincristine, Adriamycin, Actinomycin D, Ifosfamide Combination Chemotherapy in Ewing's Sarcoma

Study Overview
=================
Brief Summary
-----------------
Phase II Pilot Study of Vincristine, Adriamycin, Actinomycin D, Ifosfamide combination chemotherapy in Ewing's Sarcoma

Conditions
-----------------
Ewing's Sarcoma

Intervention / Treatment
-----------------
* Drug: Vincristine, Actinomycin-D, Ifosfamide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with Ewing's Sarcoma
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Vincristine, Actinomycin-D, Ifosfamide|Chemotherapy|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy |  | overall |
Biomarkers in Chronic Arthritis

Study Overview
=================
Brief Summary
-----------------
Use of genotyping for the optimization of treatment with biologics in chronic arthritis by looking for an association between certain alleles and response to treatment.

Detailed Description
-----------------
Chronic arthritis in children and in adults represent a public health problem in number and difficulty of treatment. 30% of patients are non-responders and / or relapse upon discontinuation of treatment. Some of these treatments are not always well tolerated, sometimes with infectious complications including tuberculosis limiting the use of biological therapies. This study will validate a battery of genetic markers to predict responders biotherapy, determine the prognosis of patients, these treatments are reserved for the most severe forms, and thus improve the care of patients.

Official Title
-----------------
Evaluation of Predictive Genetic Markers of Response to Biologic Therapies in Chronic Arthritis

Conditions
-----------------
Chronic Arthritis

Intervention / Treatment
-----------------
* Other: Blood sample


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients treated with biotherapy may be included in this study with all information necessary for regular medical consultations (filling specific monitoring by GPs questionnaires), physical therapists visits, occupational therapists, psychologists.. etc Exclusion Criteria: Patients treated with biological therapy for non rheumatic disease Other inflammatory diseases such as Crohn's disease Refusal to participate in the collection

Ages Eligible for Study
-----------------
Minimum Age: 3 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Blood sample|Conservation at the end of the blood sample|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of responsive patients with a given polymorphism (%) |  | At the inclusion | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Distribution of patients with a given biotherapy (%) |  | At the inclusion | 
| Distribution of patients presenting a given polymorphism (%) |  | At the inclusion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Biomarkers, Genetic, Chronic arthritis, Treatment
The Management of Schizophrenia in Clinical Practice (MOSAIC)

Study Overview
=================
Brief Summary
-----------------
This study is a disease-based registry designed to follow patients with a DSM-IV-TR (Diagnostic and Statistic Manual of Mental Disorders, Text Revision) diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder treated in usual care settings for up to 5 years. The registry seeks to describe the course of disease in schizophrenia, including cognitive function and negative symptoms, its treatment, and its burden of disease for participants, caregivers, clinicians, and society as a whole.

Official Title
-----------------
A Prospective, Non-Interventional Registry of Diverse Patients With Schizophrenia Across the Disease Spectrum in Usual Care Settings: Course of Disease, Treatments, and Burden of Illness

Conditions
-----------------
Schizophrenia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients, >/= 18 years of age DSM-IV-TR diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder Participants presenting with the normal course of care in usual treatment settings Able to read and speak English Able and willing to provide informed consent Able and willing to comply with the study protocol Exclusion Criteria: Participants enrolled as subjects in clinical trials at registry enrollment Participants anticipating they will be unable to participate in regularly scheduled assessments as per protocol

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cohort<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Positive and Negative Symptoms of Schizophrenia (PANSS) |  | up to 5 years | 
| Clinical Global Impression Schizophrenia Scale (CGI-SCH) |  | up to 5 years | 
| Cognitive function (Fluency, Digit Symbol-Coding, Trail Making Test) |  | up to 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Negative Symptom Assessment Scale (NSA4) |  | up to 5 years | 
| Pharmacologic/behavioural treatments used in usual care settings: intervention |  | up to 5 years | 
| Pharmacologic/behavioural treatments used in usual care settings: dose |  | up to 5 years | 
| Pharmacologic/behavioural treatments used in usual care settings: duration |  | up to 5 years | 
| Personal and Social Performance (PSP) |  | up to 5 years | 
| Schizophrenia Quality of Life Scale (SQLS) |  | up to 5 years | 
| Schizophrenia Caregiver Questionnaire |  | up to 5 years | 
| Maslach Burnout Inventory (MBI) |  | up to 5 years |
Peripheral Vision Training Study

Study Overview
=================
Brief Summary
-----------------
This study will train participants (young people and older adults) to do a visual task, and will assess whether this results in changes in behavioral assessments. In some participants, we will be also testing whether MRI measures (cortical thickness, functional connectivity) change with training.

Official Title
-----------------
Peripheral Vision Training Study

Conditions
-----------------
Visual Impairment, Cognitive Change

Intervention / Treatment
-----------------
* Other: computerized training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Right handed individuals Aged 19-89 In good health as self-reported or visual impairments due to partial vision loss Normal or corrected-to-normal vision with contact lenses or visual impairments due to partial vision loss Exclusion criteria: Younger than 18 or older than 89 Being hearing-impaired Not in good health except due to partial vision loss Having a previous serious head injury or neurological disorder, or loss of consciousness for more than 2 minutes Having hallucinations or delusions Having a current or past history of a substance abuse disorder Currently taking psychoactive medications

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 89 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Training<br>Computerized vision training | Other: computerized training<br>* Computerized training<br>|
| Sham Comparator: Control<br>Sham | Other: computerized training<br>* Computerized training<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| scores on acuity tests | scores on acuity tests | baseline | 
| scores on acuity tests | scores on acuity tests | immediately following training | 
| scores on spatial attention tests | scores on spatial attention tests | baseline | 
| scores on spatial attention tests | scores on spatial attention tests | immediately following training | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in cortical thickness | Increases in cortical thickness in areas corresponding to trained visual field | baseline and immediately following training | 
| Changes in functional connectivity | Changes in functional connectivity of areas corresponding to trained visual field | baseline and immediately following training |
Intraprostatic Botulinum Toxin Type A Injection in Patients With Benign Prostatic Hyperplasia and Unsatisfactory Response to Medical Therapy

Study Overview
=================
Brief Summary
-----------------
The injection of botulinum neurotoxin A into the prostate represents an alternative, minimal invasive treatment in patient with lower urinary tract symptoms (LUTS) associated to benign prostatic hyperplasia (BPH). Objective: To evaluate the effectiveness of BTA in treating patients with symptomatic BPH and unsatisfactory response to combined medical therapy.

Official Title
-----------------
Intraprostatic Botulinum Toxin Type A Injection in Patients With Benign Prostatic Hyperplasia and Unsatisfactory Response to Medical Therapy: a Randomised, Double-blind, Controlled Trial Using Subjective and Objective Outcomes

Conditions
-----------------
Benign Prostatic Hyperplasia (BPH), Benign Prostatic Enlargement (BPE)

Intervention / Treatment
-----------------
* Drug: BOTOX


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Moderate-to-severe LUTS as determined by the International Prostate Symptom Score Mean peak urinary flow rate of no more than 15 mL/s with a voided volume of at least 150 mL, or postvoid residual urine volume (PVR) of more than 100 ml and urodynamic parameters indicative of bladder outlet obstruction (BOO) according to International Continence Society Exclusion Criteria: Patients with neurogenic voiding disorders, prostate or bladder cancer, bladder stones, urethral stricture, chronic bladder catheterization were excluded from the study.

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: BOTOX<br> | Drug: BOTOX<br>* Botulinum Toxin type A, 200-300 UI dilued in 6 ml of saline solution<br>* Other names: Botulinum toxin type A;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| evaluation of symptomatic improvement after treatment as measured by the IPSS score. A successful outcome was defined as a reduction of IPSS score of > 50% from baseline. |  | 3 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| safety and tolerability of treatment | Quality of life improvement as measured by QoL score, changes in prostate volume, total PSA levels, maximal flow at uroflowmetry, post-void residual urine,maximal cystometric capacity, Bladder Outlet Obstruction Index, sexual modifications evaluated by International Index of Erectile Function. | 3 month |
Scleral Response to Intraocular Pressure (IOP)

Study Overview
=================
Brief Summary
-----------------
The study evaluated changes in the depth of the lamina cribrosa at different eye pressures.

Detailed Description
-----------------
Participants were glaucoma patients who during routine care were observed at different eye pressures. Images taken with an optical device that is routinely used in such patients were analysed.

Official Title
-----------------
Scleral Response to Intraocular Pressure (IOP)

Conditions
-----------------
Glaucoma, Open-Angle

Intervention / Treatment
-----------------
* Other: there was no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: glaucoma patients Exclusion Criteria: non-glaucoma patients

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: there was no intervention|patients were observed during routine care on separate times when their eye pressure was different on one day from another.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anterior lamina cribrosa depth change | Position of anterior lamina observed by optical coherence tomography (OCT) imaging. Measured in micrometers (um). | Up to 2 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
biomarker
Impact of Metformin on In Vitro Fertilization Outcomes in Overweight and Obese PCOS Women

Study Overview
=================
Brief Summary
-----------------
RCT to investigate whether metformin co-treatment would improve IVF outcomes in overweight and obese women with PCOS.

Official Title
-----------------
Impact of Metformin on In Vitro Fertilization Outcomes in Overweight and Obese Polycystic Ovary Syndrome Women; A Quasi Experimental Study

Conditions
-----------------
Polycystic Ovary Syndrome

Intervention / Treatment
-----------------
* Drug: Metformin
* Other: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The inclusion criteria restricted the patients to 39 years old with basal FSH < 10 IU/ml and normal TSH and prolacin. Exclusion Criteria: Exclusion criteria were diabetes mellitus (excluded by GTT), renal or liver disease, associated male factor, documented tubal factor or pelvic adhesions, elevated 17 alfa hydroxyprogesterone level and FSH ≥10 IU/ml. We also excluded the women who started program or medications to reduce their weight and those who their partner has abnormal semen parameters according to the world health organization parameters (WHO, 2010)

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Metformin-treated group<br>51 overweight and obese women (BMI>24) with PCOS underwent their first fresh autologous IVF-embryo transfer cycle | Drug: Metformin<br>* The metformin-treated group received metformin (1000 mg per day) with the start of controlled ovarian stimulation (COH) until the day of the pregnancy check.<br>|
| Placebo Comparator: Placebo<br>A cohort of fifty-one cross matched PCOS women | Other: Placebo<br>* Placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total number of retrieved oocytes |  | Two weeks Metformin treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Live birth rate |  | End of the pregnancy |
Women's Estrogen for Stroke Trial (WEST)

Study Overview
=================
Brief Summary
-----------------
To determine if estrogen hormone replacement therapy reduces the risk of stroke or death in postmenopausal women who have already had stroke or a transient ischemic attack (TIA).

Detailed Description
-----------------
The researchers enrolled 664 postmenopausal women with an average age of 71 years who had experienced an ischemic stroke or a TIA within the previous 90 days. Ischemic strokes and TIAs result from blockages in the vessels that supply blood to the brain. Participants were given a number of initial assessments, including the NIH Stroke Scale (NIHSS) of neurological impairment and the Barthel index of functional ability in activities of daily living. In addition to the usual best care for patients who have had a stroke, women in the trial received either oral estrogen (estradiol 17-beta at the standard replacement dose of 1 mg daily) or a matching placebo. Patients were studied for an average of 2.8 years. They stopped receiving the estrogen or placebo if they had a stroke. The researchers found that there was no significant difference in the incidence of stroke or death in the women who were randomly assigned to receive estrogen instead of placebo. However, they found that the incidence of death due to stroke was higher in the estrogen group and that the non-fatal strokes in that group were associated with slightly worse neurological and functional impairments at 1 month after stroke. The risk of stroke within the first 6 months after enrollment in the study was also higher among women in the estrogen group. There were no significant differences between treatment groups in the number of TIAs or non-fatal heart attacks. However, participants receiving estrogen were more likely to experience gynecologic complications, particularly vaginal bleeding.

Conditions
-----------------
Stroke

Intervention / Treatment
-----------------
* Drug: estrogen


Participation Criteria
=================

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: estrogen|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
stroke, estrogen
Astigmatic Changes Secondary to Eyelid Surgeries

Study Overview
=================
Brief Summary
-----------------
Eyelid surgeries change the lid position over the cornea. Previous surgeries evaluated astigmatic corneal changes in children undergoing ptosis repair. Only several studies evaluated astigmatic changes following eyelid surgeries in elderly patients. The investigators aim is to estimate this change, implications on corneal astigmatism may have great effect to future cataract surgeries for this group of patients.

Detailed Description
-----------------
Patients registered for a lid surgery due to blepharoptosis or ptosis will undergo a topographic examination prior to and 3 months post operative in addition to their regular pre and post operative examination astigmatic shift will be mathematically measured.

Official Title
-----------------
Astigmatic Corneal Changes Secondary to Eyelid Surgery

Conditions
-----------------
Blepharoptosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: upper lid blepharochalasis Exclusion Criteria: prior eyelid trauma mental retardation or other causes preventing from signing an agreement form

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| eyelid displacement<br>patients suffering from eyelid disposition due to ptosis, blepharochalasis and are registered for eyelid surgeries will be assigned for the study | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| astigmatic corneal decrease following eyelid surgery | eyelid change in position will change the effect on corneal astigmatism measured 3 months post surgery | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| type of astigmatism | a change from against the rule astigmatism to with the rule astigmatism following eyelid surgery will be evaluated | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
astigmatism, lid surgery, older than 40 years, can sign an acceptance form, uper lid surgery